The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

The FDA has since said it is reviewing its decision. Last week, Novo Nordisk (NVO) asked the FDA to have semaglutide placed on the Demonstrable Difficulties for Compounding List, arguing that ...

Novo Nordisk has blockbuster hopes for its GLP-1 semaglutide type 2 diabetes drug, which is edging towards approval in major markets – but it won't have a cardiovascular protection indication.

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

After the FDA declared a semaglutide shortage in 2022, pharmacies, telehealth companies and other health care providers have been able to manufacture copycat versions of Novo Nordisk‘s GLP-1 ...

Patients are encouraged to only acquire authentic Novo Nordisk Ozempic ® (semaglutide) injection 1 mg through pharmacies and to check the product for any signs of counterfeiting before using.